Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study
| Autor: | Jean-François Bosset, André Dubiez, Valérie Magnin, Bertrand Mennecier, Virginie Westeel, P. Jacoulet, Alain Depierre |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Urology Phases of clinical research Small-cell carcinoma Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Humans Medicine Prospective Studies Carcinoma Small Cell Lung cancer Survival rate Etoposide Aged Aged 80 and over Chemotherapy business.industry Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Surgery Regimen Treatment Outcome Oncology Injections Intravenous Female Cisplatin Prophylactic cranial irradiation business medicine.drug |
| Zdroj: | Lung Cancer. 27:137-143 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/s0169-5002(99)00103-8 |
| Popis: | Thirty-one previously untreated patients with limited stage small-cell lung cancer (LSCLC) were included in a prospective study, to investigate the feasability and the efficacy of a combined modality treatment using concurrent hyperfractionated chest irradiation and cisplatin (P) plus etoposide (E) chemotherapy. All patients received intravenously P=75 mg/m 2 at day 1, plus E=120 mg/m 2 days 1–3, at 3-week intervals for six cycles. Irradiated patients received 45 Gy in two daily fractions, 5 days a week, from week 4 to week 6. During week 5, prophylactic cranial irradiation was initiated, in one daily fraction of 2.5 Gy for a total dose of 25 Gy. Twenty-nine patients were evaluable for response. Twenty-two (76%) achieved a complete response, five (17%) had a partial response. Five patients are currently alive. The overall response rate was 93% (CI 95% (83.7–100)). The median survival time was 14 months and the 2-year survival rate was 25%. Main toxicities were grade 3–4 esophagitis in half of the patients and myelosuppression. The results are not as optimistic as other studies using a similar regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect